Abstract:Background and Purpose: Atherosclerosis is vascular disease of chronic inflammation and lipid disorder, which is a major cause of coronary heart disease. Foam cell formation is key progress during the atherosclerosis development. Insulin-like growth factor (IGF)-1 is a growth hormone that plays a crucial role in growth, metabolism, and homeostasis. Previous studies have demonstrated that increase in circulating IGF-1 can reduce atherosclerotic burden. However, active IGF-1 is characterized with poor tissue retention and is at a very low level in circulation system. Therefore, supplementation of exogenous IGF-1 to restore the physiological level is a promising approach to inhibit atherosclerosis. In this study, we develop a self-assembling, anti-inflammatory drug-modified peptide derived from IGF-1 to mimic IGF-1 bioactivity and simultaneously with an anti-inflammatory property for the treatment of atherosclerosis. Methods: ApoE(-/-) mice were subcutaneously (s.c.) injected with the different hydrogels or natural IGF-1 protein solution per week and simultaneously fed a high-fat diet for 16 weeks. Atherosclerotic lesion formation and stability were assessed after treatment. Moreover, peritoneal macrophage and serum samples were collected to determine lipid profile and inflammatory cytokines. Concurrently, we determined the effect of bifunctional supramolecular nanofibers/hydrogel on cholesterol efflux, foam cell formation, phenotypic transformation of VSMC to macrophage-like cells, and macrophage polarization in vitro or in vivo. Results: Bifunctional supramolecular nanofibers/hydrogel for the treatment of atherosclerosis was formed by a short peptide consisting of a tetrapeptide SSSR from C-region of growth factor IGF-1, an anti-inflammatory drug naproxen (Npx), and a powerful self-assembling D-peptide (FF)-F-D-F-D. The resulting hydrogel of Npx-(D)F(D)FGSSSR (Hydrogel 1, H1) possessed both the anti-inflammatory and IGF-1 mimicking properties, and it efficiently promoted the expression of ABCA1 and ABCG1, thereby significantly reducing cholesterol accumulation in macrophages and preventing foam cell formation. Moreover, H1 markedly inhibited the transformation of vascular smooth muscle cells (VSMCs) into macrophage-like cells which also contributed to foam cell formation. In addition, H1 significantly reduced the inflammatory response in vitro and in vivo. Most importantly, the IGF-1 mimetic peptide showed comparable performance to IGF-1 in vivo and inhibited atherosclerosis by markedly reducing lesion area and enhancing plaque stability. Conclusions: Our study provides a novel supramolecular nanomaterial to inhibit pathological progress of atherosclerosis through regulating cholesterol efflux and inflammation, which may contribute to the development of a promising nanomedicine for the treatment of atherosclerosis in the clinic.

A novel apoA-I mimetic peptide suppresses atherosclerosis by promoting physiological HDL function in apoE<SUP>-/-</SUP>mice

ApoA-I Mimetic Peptides Promote Pre-Β HDL Formation in Vivo Causing Remodeling of HDL and Triglyceride Accumulation at Higher Dose

Apolipoprotein and LRP1-Based Peptides as New Therapeutic Tools in Atherosclerosis

Systematic Evaluation of the Effect of Different Apolipoprotein A-I Mimetic Peptides on the Performance of Synthetic High-Density Lipoproteins in Vitro and in Vivo

A Human Apolipoprotein E Mimetic Peptide Reduces Atherosclerosis in Aged Apolipoprotein E Null Mice.

Apolipoprotein A-I Mimetic Peptide Inhibits Atherosclerosis by Altering Plasma Metabolites in Hypercholesterolemia.

Protective Effect and Mechanism of Apolipoprotein A-1 Mimetic Peptide L-4F on Atherosclerosis in Mice Model

Effect of The Apolipoprotein E Mimetic Peptide EpK on Atherosclerosis in apoE(-/-) Mice

Effect of Apolipoprotein A-I Mimetic Peptides on Cholesterol Efflux in RAW264.7 Cells

Adenosine Monophosphate-activated Protein Kinase Induces Cholesterol Efflux from Macrophage-derived Foam Cells and Alleviates Atherosclerosis in Apolipoprotein E-deficient Mice,

Bifunctional supramolecular nanofiber inhibits atherosclerosis by enhancing plaque stability and anti-inflammation in apoE -/- mice.

Apolipoprotein A-I mimetic peptide inhibits atherosclerosis by increasing tetrahydrobiopterin via regulation of GTP-cyclohydrolase 1 and reducing uncoupled endothelial nitric oxide synthase activity

HDL Mimetic Peptides.

Function of Different Proportions of Apolipoprotein A-I Cysteine Mutants and Apolipoprotein A-V on Recombinant High-Density Lipoproteins in Vitro.

D-4F, an apolipoprotein A-I mimetic peptide, promotes cholesterol efflux from macrophages via ATP-binding cassette transporter A1.

Apolipoprotein A-I Mimetic Peptide Restores VEGF-induced Angiogenesis in Hypercholesterolemic Ischemic Heart by Reducing HDL Proinflammatory Properties

Modulation of Recombinant Antigenic Constructs Containing Multi-Epitopes Towards Effective Reduction of Atherosclerotic Lesion in B6;129S-Ldlr(tm1Her)Apob(tm2Sgy)/J Mice.

The apolipoprotein A-I mimetic peptide, D-4F, alleviates ox-LDL-induced oxidative stress and promotes endothelial repair through the eNOS/HO-1 pathway

Myriocin and D-PDMP Ameliorate Atherosclerosis in ApoE &Lt;sup>-/-</sup> Mice Via Reducing Lipid Uptake and Vascular Inflammation

Apob-100 And Hsp60 Peptides Exert A Synergetic Role In Inhibiting Early Atherosclerosis In Immunized Apoe-Null Mice

Development of Innovative Antiatherosclerotic Peptides through the Combination of Molecular Modeling and a Dual (Biochemical‐Cellular) Screening System